NCT03563599View on ClinicalTrials.gov

A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 23, 2018

Primary Completion Date

September 9, 2019

Study Completion Date

September 9, 2019

Conditions

Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB

Interventions

DRUG

Telacebec (Q203)

High, Mid, Low dose of telacebec

DRUG

Rifafour e-275

RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)

Trial Locations (2)

Unknown

TASK Applied Science, Cape Town

UCT Lung Institute, Cape Town

All Listed Sponsors

lead

Qurient Co., Ltd.

INDUSTRY

NCT03563599 - A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) | Biotech Hunter | Biotech Hunter